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levels were similar. During chemotherapy, the levels of all 4 
cytokines increased. We evaluated these responses sepa-
rately in patients that did and did not clear their sputum cul-
ture at 2 and 6 months. At 2 months, decreases in both IFN-  
and IL-12 correlated strongly with a successful early response, 
while after 6 months of therapy, when half (7/14) of MDR-TB 
patients were still sputum culture positive, downregulation 
of TNF-  was uniquely correlated with sputum conversion 
between the groups.  Conclusion: Our findings suggest the 
possibility that the regulation of TNF-  production in whole 
blood may be a more specific indicator of sputum conver-
sion at 6 months than IFN-  , IL-12 or IL-10 in MDR-TB pa-
tients.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Mycobacterium tuberculosis  (Mtb) is the causative 
agent of pulmonary tuberculosis (TB). Currently, there 
are two major problems facing the medical community 
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 Abstract 
 Background: We have previously reported that TNF-  levels 
correlate to total mycobacterial burden in tuberculosis (TB) 
patients.  Objective: To characterize the dynamics of cyto-
kine responses in TB patients during chemotherapy to iden-
tify potential surrogate markers for effective treatment. 
 Methods: Following induction by culture filtrate proteins in 
whole blood, production patterns of TNF-  , IL-10, IFN-  and 
IL-12 were measured in 23 non-multidrug-resistant (MDR)-TB 
and 16 MDR-TB patients and in 31 healthy controls. Rates of 
mycobacterial clearance from the sputum were then mea-
sured and compared.  Results: Prior to the initiation of che-
motherapy, TNF-  and IL-10 levels were significantly higher 
in TB patients than in healthy controls while IFN-  and IL-12 
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concerning the fight against Mtb. First, the increasing 
emergence of multidrug-resistant (MDR)-TB has ren-
dered common therapies against the bacteria ineffective. 
Second, the current testing methodologies for the diag-
nosis of TB are extremely slow. Because Mtb is a slow-
growing organism, it can take up to 8 weeks for an accu-
rate Mtb diagnosis to be made. As a result, there is an 
increasing need for both novel therapies and rapid diag-
nostic methods.
 After Mtb infection, healthy individuals develop a cel-
lular immune response, which arrests the growth of the 
microorganism, preventing progression to clinical TB  [1, 
2] . However, susceptible individuals develop pulmonary 
TB. Upon inhalation of aerosolized Mtb, the pathogen is 
engulfed by macrophages. Once inside the phagosome, 
virulent Mtb inhibits the acidification of the compart-
ment  [3] . This inhibition allows the bacilli to reside with-
in the macrophage, sequestered away from the bacteri-
cidal and antigen-generating machinery of the cell. As a 
result, Mtb establishes a safe and long-term resting area 
for replication, which eventually results in cell lysis and 
bacterial spread. 
 Upon stimulation by a pathogen, macrophages engulf 
the offending particle, and upon its destruction, they 
present smaller peptide antigens on their surface. These 
antigens are then recognized by Th1 cells, which in turn 
secrete various cytokines, including IFN-  , IL-12 and 
TNF-  . These cytokines in turn activate resting macro-
phages, which trigger the immune response. In order to 
suppress the immune response once an infection has 
been cleared, and to prevent autoimmune responses to 
self-antigens, other cytokines downregulate the immune 
system. IL-10 activates B and Th2 cells while inhibiting 
Th1 cytokine production. Activated Th2 cells secrete IL-
4, which also inhibits Th1 cell activity and inactivates 
macrophages.
 Previously, it has been reported that Mtb stimulation 
of peripheral blood mononuclear cells (PBMCs) isolated 
from TB patients resulted in a diminished production 
and expression of Th1 cytokines, including IFN-  and 
IL-2  [4] . Additionally, this same report demonstrated that 
after 9 months of drug therapy, IFN-  levels were mark-
edly increased, coinciding with successful treatment. As 
a result, it has been suggested that different clinical states 
of Mtb can be correlated with cytokine profiles.
 In an effort to reduce the amount of time required to 
accurately diagnose an Mtb infection, some attention is 
being focused on identifying biomarkers of Mtb infec-
tions; examples include molecules that are secreted by the 
pathogen itself, or host factors derived from immune re-
sponses. In this study, we build upon our previous find-
ings that TNF-  , IFN-  and IL-10 profiles are distinct in 
non-MDR-TB versus MDR-TB patients  [5] . Using spu-
tum clearance as an indicator of positive responses to 
chemotherapies, we report that patients on anti-Mtb che-
motherapies have altered TNF-  and IFN-  levels that 
correlate with favorable responses to the drugs. As a re-
sult, we propose that these cytokines, particularly TNF-
  , could serve as potential biomarkers for response to 
therapy. 
 Patients and Methods 
 Study Subjects 
 A total of 39 patients (35 men and 4 women) who were diag-
nosed with active TB by clinical findings, radiological examina-
tion and the demonstration of acid-fast bacilli (AFB) in their 
sputum at the National Masan TB Hospital (NMTH) were en-
Table 1. Sputum culture AFB-negative conversion rate in non-MDR and MDR-TB patients along with ther-
apy
Patients enrolled Sputum culture AFB
non-MDR-TB (n = 23) MDR-TB (n = 16) total (n = 39)
– + – + – +
At enrollment 12 (54.5%) 10 (45.5%) 0 (0 %) 16 (100 %) 12 (31.6%) 26 (68.4%)
After 2 months 21 (95.5%) 1 (4.5%) 2 (12.5%) 14 (87.5%) 23 (60.5%) 15 (39.5%)
After 6 months 22 (100%) 0 (0.0%) 8 (50.0%) 8 (50.0%) 30 (78.9%) 8 (21.1%)
One of the 39 patients enrolled who was culture negative at enrollment and not responsive to therapy was 
omitted from the analysis.
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rolled for this study ( table 1 ). Thirty-one bacillus Calmette-
Guérin (BCG)-vaccinated, healthy individuals (15 men and 16 
women) also participated as controls. The study protocol was 
approved by the NMTH Institutional Ethics Committee and 
written informed consent was obtained from each study sub-
ject.
 Sputum Culture and Drug Susceptibility Test  
 Sputum culture positivity for Mtb was confirmed both by 
BacT/Alert and conventional Ogawa media. Briefly, sputum spec-
imens were decontaminated with N-acetyl- L -cysteine/4% NaOH 
and inoculated into BacT/Alert and Ogawa media. When the Oga-
wa growth was detected as positive, a drug susceptibility test was 
carried out on Löwenstein-Jensen plates containing anti-TB 
drugs. The ‘absolute concentration method’ was used as previ-
ously described  [6, 7] . The critical concentration for isoniazid and 
rifampin was 0.2 and 40   g/ml, respectively. All inoculated slants 
were incubated at 37 ° C and growth was checked visually every 
week. The sputum culture staining for AFB was assessed at the 
time of admission, and 2 and 6 months after starting proper treat-
ment. 
 Blood Collection and Cytokine Whole-Blood Assay 
 Blood samples were drawn into heparinized Vacutainers and 
processed within 2 h for the cytokine whole-blood assay  [5, 8] . 
Blood was collected at the time of admission, and 2 and 6 months 
after the start of treatment prescribed by NMTH staff. Blood di-
luted with RPMI-1640 (1: 10) containing penicillin-streptomycin 
(Gibco) and 10% fetal bovine serum was distributed into 96-well 
plates and cultured in triplicate in the presence of medium alone 
or with phytohemaggultinin (PHA) or lipopolysaccharide (LPS; 
Sigma-Aldrich, St. Louis, Mo., USA) or culture filtrate protein 
(CFP) at a final concentration of 10   g/ml. Cultures were main-
tained in a 5% CO 2 atmosphere at 37 ° C. Cultured supernatants 
were harvested 1, 3 and 6 days after culturing, and stored at –70 ° C 
until use. Cytokines were measured at day 1 for IL-12 and IL-10, 
day 3 for TNF-  and day 6 for IFN-  (optimal time points for each 
cytokine were determined by preliminary experiments, data not 
shown). 
 Measurement of Cytokines by ELISA 
 For cytokine analysis, two-site capture immunoassays with 
OptEIA monoclonal antibody sets (BD Pharmingen, Los Angeles, 
Calif., USA), streptavidin-horseradish peroxidase conjugate and 
recombinant cytokines as standards were used. Briefly, 96-well 
plates were coated with capture antibodies to each cytokine (IFN-
  , IL-12, TNF-  and IL-10) according to the manufacturer’s pro-
tocol. The concentrations were given in the ELISA set instruc-
tions as dilution factor, 1: 250. Plates were incubated overnight at 
4 ° C and blocked at room temperature with 5% FBS in PBS for
1 h. The plates were washed three times. Samples were added and 
incubated for 2 h at room temperature. Working detector (detec-
tion antibody + avidin-HRP reagent) was added to each well and 
the plate was incubated for 1 h at room temperature. After wash-
ing 7 times, substrate solution (BD Pharmingen TMB substrate 
reagent set) was added to each sample. The plates were incubated 
for 30 min and the reaction was stopped by adding stop solution. 
The plates were read at 450 nm in an ELISA reader (OPTImax, 
Sunnyvale, Calif., USA). A standard curve was generated from the 
known concentration of the standard according to the method 
provided in the kit. Cytokine levels were calculated from the stan-
dard curve by computing absorbance values against the test con-
centration. Detection limits of the cytokine kits used were as fol-
lows: IFN-  – 5 pg/ml; IL-12 – 7.5 pg/ml; TNF-  – 15 pg/ml, and 
IL-10 – 7.5 pg/ml.
 Statistical Analysis 
 The Mann-Whitney U test was used for data analysis between 
groups. Differences were considered significant when p  ^  0.05. 
 Results 
 Patient Description and Response to Chemotherapy 
 Thirty-nine subjects were enrolled in this study ( ta-
ble 1 ). All subjects were examined for clinical symptoms 
and underwent standard radiographic assessment. The 
mean age of the patients was 49.4  8 2 years (range, 22–87 
years). They included 14 newly diagnosed, 6 relapse, 7 
chronic, 6 treatment failure, and 6 default cases as de-
fined by the World Health Organization  [9] . One case of 
pneumothorax was observed and 11 subjects had con-
comitant diabetes mellitus, and 1 had hypertension. None 
of the patients were HIV positive. At the time of initial 
blood sampling, the patients had been started on chemo-
therapy for  ! 1 week. Thirty-one  Microbacterium bovis 
 BCG-vaccinated, healthy individuals (15 men and 16 
women) also participated as controls, and their mean age 
was 34.6  8 1.5 years (range, 23–54 years). Of the 39 TB 
patients, 10 were culture-confirmed non-MDR-TB while 
16 were culture-confirmed MDR-TB patients. Thirteen 
of the initial patients were sputum culture negative at the 
start of the therapy, and remained so throughout the 6-
month study. Although they were culture negative, 12 of 
13 of these patients experienced significant clinical im-
provement with normal first-line chemotherapy during 
the course of this study while 1 patient did not. For that 
reason, this non-responsive patient was omitted from 
further analysis. In total, therefore, 38 patients were con-
sidered to have diagnosed as TB and were included in 
subsequent analysis: 22 had drug-susceptible disease and 
16 MDR disease.
 Of the 10 sputum-positive drug-susceptible subjects, 9 
had achieved sputum conversion after the first 2 months 
of therapy, and the last subject achieved sputum conver-
sion after 6 months. In total, 100% of the non-MDR-TB 
subjects were sputum negative at the end of the therapy. 
Of the 16 MDR-TB subjects, only 2 subjects had achieved 
sputum conversion after 2 months. After 6 months of 
treatment, an additional 6 subjects (8 in total) had con-
verted. In total, 50% of the MDR-TB patients had con-
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verted to sputum negative by the conclusion of the study 
( table 1 ). 
 Whole-Blood Cytokine Profiles during Chemotherapy 
 To explore whether changes in cytokine responses be-
fore, during and after 6 months of drug therapy would 
provide a surrogate marker for sputum smear and cul-
ture, we collected whole blood from healthy volunteers
(n = 31) and our cohort of TB patients. This blood was 
stimulated with CFP from Mtb and 4 cytokines were 
measured: IFN-  , TNF-  , IL-10 and IL-12 ( fig. 1 ). 
 At the start of treatment, there was no significant dif-
ference in the IFN-  and IL-12 levels between TB patients 
and healthy controls. IFN-  levels increased with therapy 
by 2 months (p  ^  0.05) and reached a plateau almost 
threefold higher compared to levels before treatment by 
6 months of therapy. IL-12 levels similarly increased after 
2 months of therapy (p  ^  0.01) but decreased to levels 
before therapy by 6 months ( fig. 1 ). In contrast, signifi-
cantly higher levels of TNF-  and IL-10 were observed in 
TB patients than healthy controls at the start of the treat-
ment, and these cytokine levels also increased during 
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 Fig. 1. Cytokine profiles and modulation by chemotherapy in whole blood from TB patients in comparison to 
healthy controls. Whole blood was incubated with CFP (10   g/ml) for 1, 3 or 6 days and cytokine concentra-
tions were assessed by ELISA. Each patient is represented by entry, and 2- and 6-month measurements (the 
mean of triplicate cultures after deducting the medium alone value).  a p  ^  0.05,  b p  ^  0.01 and  c p  ^  0.001. 
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drug treatment ( fig. 1 ). In general, all 4 cytokines showed 
a complex dynamic response that appeared to fall into 
one of two general trends: either a transient increase at 2 
months followed by a return to baseline levels at 6 months, 
or an increase at 2 months followed by a further increase 
at 6 months.
 Cytokine Response Pattern Does Not Correlate with 
MDR Status But Is Mtb Specific 
 In an attempt to understand whether these two pat-
terns of response were the result of previous treatment 
history or were specific to strains of Mtb that had drug 
resistance, we divided the patients into non-MDR- and 
MDR-TB groups and examined patterns of cytokine pro-
duction between these groups, but no significant differ-
ences were observed ( fig. 2 ). Likewise, when comparing 
sputum culture-negative subjects that showed clinical 
improvement to sputum culture-positive patients, no dif-
ferences in responses of cytokine profiles were observed 
(data not shown).
 In order to verify that the cytokine responses seen 
were in fact specific to the Mtb antigens present in CFP, 
we stimulated the same blood samples with non-TB-re-
lated mitogens to activate the aforementioned cytokines. 
For these purposes, PHA was used to stimulate IFN-  
and IL-10, while LPS was used for TNF-  and IL-12 stim-
ulation ( fig. 3 ). No changes in IFN-  levels were observed 
between these groups during therapy. Similar results 
were obtained with TNF-  and IL-12 when comparing 
CFP and mitogen stimulation. Interestingly, PHA-in-
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 Fig. 2. Comparison of cytokine production and modulation by chemotherapy between non-MDR and MDR-TB 
patients. Whole blood was incubated with CFP (10   g/ml) for 1, 3 or 6 days and cytokine concentrations were 
assessed by ELISA. Each value was calculated as the mean of triplicate cultures after deducting the medium 
alone value. Results are represented as means  8 SEM.  
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duced IL-10 production showed a reverse correlation with 
PHA induction ( fig. 3 ). 
 Effect of Sputum Clearance Rate on Cytokine 
Production Patterns 
 In an effort to see if the cytokine production patterns 
correlated with sputum conversion, we obtained sputum 
cultures from each subject at the time of blood drawing 
for cytokine assays and used these results to identify the 
sputum-positive or sputum-negative status at each time 
point ( fig. 4 ). Prior to the start of therapy, IFN-  levels 
were overall lower in the 12 sputum culture-negative sub-
jects compared to the culture-positive subjects, a trend 
that continued when comparing groups of patients who 
had achieved a culture-negative status compared to those 
who remained culture positive at each time point through-
out the study. At the end of the treatment, those who re-
mained culture positive had dramatically increased 
amounts of IFN-  compared to levels both before the 
therapy and after 2 months even compared to those who 
had converted at 6 months. A similar pattern to IFN-  
levels was seen with IL-12. Lower levels of IL-12 were re-
leased in the patients who had converted to culture nega-
tive than those who failed to at every time point. This 
result was statistically significant (p  ! 0.05) after 6 months 
of therapy ( fig. 4 ).
 TNF-  and IL-10 showed somewhat different patterns 
than IFN-  and IL-12 in this cohort. Prior to therapy, 
sputum-positive and sputum-negative subjects had simi-
lar levels of TNF-  and IL-12. Although statistically sim-
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 Fig. 3. Cytokine profiles in whole blood after stimulation with PHA (IFN-  and IL-10) or LPS (IL-12 and TNF-
  ) from TB patients and healthy controls. Each patient is represented by entry, and 2- and 6-month measure-
ments (the mean of triplicate cultures after deducting medium alone value).  a p  ^  0.05 and  c p  ^  0.001. 
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ilar, both groups doubled their levels at 2 months. How-
ever, a dramatic change in TNF-  was seen at 6 months, 
when the sputum-negative population returned to cyto-
kine levels before the therapy while remaining elevated in 
the sputum-positive population (p  ! 0.001). Strikingly, 
IL-10, a cytokine which is involved in helping to turn off 
the immune response, was relatively unchanged by the 
presence or absence of Mtb in the sputum of subjects be-
fore, during or after the therapy. 
 Discussion 
 Cytokine production patterns in TB patients are pre-
sumed to vary according to the disease state, and we have 
previously reported that TNF-  was associated with 
MDR-TB and mycobacterial load in sputum  [5] . Howev-
er, our previous study was cross-sectional, limiting our 
ability to evaluate these correlations as markers to poten-
tially predict outcome. In this longitudinal study, we have 
extended this observation by comparing mycobacterial 
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 Fig. 4. Comparison of cytokine production patterns between 
culture-positive (black) and -negative (empty) patients. Sputum 
cultures were performed at each time point and cytokine produc-
tion was compared between culture-positive (black) and -negative 
(empty) patients. Only those patients who were sputum culture 
positive at the previous time point were reevaluated at the next 
time point of therapy. Therefore, only 26 sputum-positive patients 
were evaluated at 2 months and only 15 sputum-positive patients 
were evaluated at 6 months. Each value was calculated as the mean 
of triplicate cultures after deducting medium alone value.  a p  ^  
0.05 and  c p  ^  0.001. 
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clearance during chemotherapy with TNF-  levels pro-
duced by stimulated whole blood in the same patients 
over time. 
 Prior to starting the therapy, TNF-  and IL-10 levels 
were significantly higher in TB patients than in healthy 
controls. These results are in agreement with other pub-
lished results for IL-10  [10, 11] and for TNF-   [12–14] . In 
contrast, IFN-  and IL-12 levels were not different be-
tween healthy controls and TB patients. Many other stud-
ies report that the production of IFN-  is depressed in TB 
patients compared to healthy individuals  [15–17] . How-
ever, conflicting reports have demonstrated no differenc-
es in IFN-  mRNA expression and the number of IFN-
  -producing cells between TB patients and healthy con-
trols  [18, 19] . This discrepancy may be explained by recent 
studies reporting that different disease states could in-
duce different IFN-  responses  [17, 20, 21] . In our patient 
cohort, during anti-TB chemotherapy, the levels of IFN-  
increased significantly after 2 months and much more 
after 6 months in TB patients, consistent with other re-
ports  [4, 8] . IL-12 also increased after 2 months of thera-
py, but after 6 months of therapy decreased again to levels 
before therapy, whereas IFN-  showed the highest pro-
duction levels at 6 months. Although IL-12 is known to 
enhance IFN-  production  [2, 22] , this observation sug-
gests IFN-  production is not dependent on IL-12 regula-
tion, as already shown in another study  [23, 24] . The de-
crease in IL-12 production after 6 months of therapy may 
be related to the increase in the anti-inflammatory cyto-
kine IL-10. IL-10 is known to be produced by macro-
phages and T cells during Mtb infection and possesses 
macrophage-deactivating properties including downreg-
ulating IL-12 production  [25] . Because IL-10 acts as an 
antagonist of TNF-  and IFN-  , it appears contradictory 
that IFN-  and TNF-  would increase concomitantly 
with IL-10. However, it is plausible to consider that IL-10 
is functioning solely to downregulate the immune sys-
tem. As drug treatment clears Mtb from the host, the 
need for IFN-  and TNF-  production decreases, an 
event regulated by IL-10. It is also in agreement with the 
drop in IL-12 to levels before the treatment, further indi-
cating a reduction in the immune response.
 IFN-  is also involved in stimulating TNF-  secretion 
 [26] . This study shows the induction of TNF-  increased 
as IFN-  production increased during the course of che-
motherapy. Mitogen-induced cytokines showed different 
profiles from CFP-induced cytokines. No changes in levels 
were observed in PHA-induced IFN-  production with 
therapy but LPS-induced IL-12 and TNF-  production 
levels correlated with those of CFP-induced levels. In con-
trast, PHA-induced IL-10 showed an inverse correlation 
with CFP-induced IL-10 production. The molecular and 
kinetic basis for this difference in response is not clear, 
however, successful therapy may have repressed the pro-
duction of this immunosuppressive cytokine by non-spe-
cific stimulation. Our findings suggest that chemotherapy 
may alter the specific cytokine production profiles.
 In order to investigate if mycobacterial clearance in-
duced by chemotherapy is mirrored by alterations in the 
cytokine response, serial sputum culture and cytokine 
measurements during therapy were examined. Almost 
all non-MDR-TB patients (9/10) who were initially spu-
tum culture positive became sputum culture negative af-
ter the first 2 months of therapy, whereas only 2 MDR-TB 
patients obtained sputum negativity. At this time point, 
both IFN-  and IL-12 production were decreased more 
in sputum-negative patients than in sputum-positive pa-
tients, indicating the normalization of the production of 
these 2 cytokines. However, no differences between pa-
tient groups were observed in TNF-  and IL-10 levels. By 
6 months after the therapy, 6 further MDR-TB patients 
had become sputum culture negative, and IFN-  and IL-
12 production also decreased in these sputum-negative 
patients compared to the persistently sputum-positive 
patients. Notably, IL-10 levels remained unchanged be-
tween the two groups. However, there was a marked re-
duction in TNF-  to levels similar to those seen in the 
group of sputum-negative patients before the therapy. 
These findings suggest the potential role of TNF-  as a 
marker for successful therapy in MDR-TB. 
 It has already been demonstrated that some MDR-TB 
patients produce lower levels of TNF-  but not IFN-  
compared with non-MDR-TB patients in PBMCs  [27] or 
in whole blood  [5] . Also, antigenic stimulation of periph-
eral blood monocytes from MDR-TB induces different 
trends of TNF-  and IL-12 production compared to those 
from non-MDR-TB patients  [27] . The production of ni-
tric oxide from peripheral blood monocytes was de-
pressed in MDR-TB patients and correlated with TNF-  
production  [28] . Conversely, sputum TNF-  levels de-
crease following initiation of treatment  [29] and a positive 
correlation was observed between mycobacterial load 
and TNF-  levels in sputum by 12 weeks of treatment 
 [29] . While this may reflect variation in the patient popu-
lations studied it is worth at least considering that this 
may reflect differential antigenicity of the TB strains that 
are more prone to develop into MDR disease. It is worth 
pointing out that at least one virulence factor of Beijing 
strains (the phenolic glycolipid) has been shown to have 
potent immunomodulatory properties  [30] .
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 TNF-  appears to be the most dynamic of the 4 cyto-
kines investigated here, a finding that should support 
further evaluation of the response of this cytokine in TB 
patients. Our results suggest CFP-induced TNF-  levels 
in whole blood are closely related to the clearance of Mtb 
in MDR-TB patients independent of IL-10 regulation and 
could be a useful indicator for monitoring response to 
therapy in MDR-TB patients. However, the sample size in 
the present study is too small to make a definitive conclu-
sion and this hypothesis will have to be validated in larg-
er patient cohorts. These studies also suggest the possibil-
ity that an immune signature that correlates with sputum 
conversion may exist that would provide an early indica-
tor for discontinuation of therapy, a significant problem 
for MDR-TB where treatment courses often exceed 2 
years. 
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